Decades of Dedication
Mark joined GSK 28 years ago as a scientist in drug discovery. In the early 2000s, he became part of the team working within Respiratory to develop a long-acting, once-daily, muscarinic antagonist (LAMA) which could be used in combination with other respiratory medicines.
As a biologist, Mark worked with a team of chemists to evaluate a number of compounds they thought might have the potential to be effective.
While he and the team saw positive results in early testing of one particular compound, they did not know if it would pass all of the hurdles required to demonstrate the efficacy and safety needed for patients. After extensive testing in the lab, working to understand how the candidate medicine functioned and impacted disease processes in tissues, Mark and the team were able to progress the key compound to early clinical studies.
“One of the most exciting moments of my career was when I joined a presentation where clinical results were shared showing the medicine’s positive results and proof of concept. The team knew then that we had potentially discovered a medicine that might benefit patients,” said Mark.
Mark is not only proud of the work of the entire team in the discovery of this medicine, but also proud of GSK’s leadership in the respiratory field.